The New International Staging System Lung Cancer



Similar documents
Survival analysis of 220 patients with completely resected stage II non small cell lung cancer

Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

Targeted Therapy What the Surgeon Needs to Know

A Practical Guide to Advances in Staging and Treatment of NSCLC

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Mesothelioma. Malignant Pleural Mesothelioma

The IASLC Lung Cancer Staging Project

Stage I Non-Small Cell Lung Cancer: Recurrence Patterns, Prognostic Factors and Survival

PET/CT in Lung Cancer

UICC World Cancer Congress. Cancer Staging and Quality of Care

TNM Classification for Lung Cancer

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Lung Cancer Treatment Guidelines

EMR Can anyone do this?

Lung Cancer and Mesothelioma

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Radiation Therapy in the Treatment of

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

Chapter 2 Staging of Breast Cancer

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Probe: Could you tell me about when?

Small Cell Lung Cancer

Diagnóstico y Terapias Locales

Lung Cancer Staging: Clinical and Radiologic Perspectives

The National Clinical Lung Cancer Audit (LUCADA)

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

Cancer of the Cardia/GE Junction: Surgical Options

Facing Lung Cancer? Learn why da Vinci Surgery may be your best treatment option for lung cancer.

Surgical therapy of. who should be operated

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

SMALL CELL LUNG CANCER

Pathology of lung cancer

The Ontario Cancer Registry moves to the 21 st Century

How To Treat Lung Cancer At Cleveland Clinic

DELRAY MEDICAL CENTER. Cancer Program Annual Report

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options

Recommendations for the Reporting of Pleural Mesothelioma

The Need for Accurate Lung Cancer Staging

CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV

Advances in Lung Cancer: A Multidisciplinary Approach

Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April :10 14:20 Room C

Lung Cancer Workup and Staging

Update on Mesothelioma

Lymph Nodes and Cancer What is the lymph system?

Thoracic 18F-FDG PETCT

PET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection

Crosswalk for Positron Emission Tomography (PET) Imaging Codes G0230 G0030, G0032, G0034, G0036, G0038, G0040, G0042, G0044, G0046

An Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Malignant pleural mesothelioma P/D vs. EPP

How To Know When To Stage Lung Cancer

How To Compare The Effects Of A Hysterectomy And A Hysterectomy

Program Chairs: Robert W. Holloway, MD and Martin Martino, MD Speakers and times are subject to change

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival

Report series: General cancer information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Screening, early referral and treatment for asbestos related cancer

TRATTAMENTO COMBINATO RADIO- CHEMIOTERAPICO NEL III STADIO NSCLC

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida

SMALL LungCancerAlliance.org

SAKK Lung Cancer Group. Current activities and future projects

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Current Status and Perspectives of Radiation Therapy for Breast Cancer

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

AJCC Cancer Staging System, 8 th Edition: UPDATE

Lung Cancer: An Overview

Male. Female. Death rates from lung cancer in USA

Transcription:

The New International Staging System Lung Cancer Valerie W. Rusch, MD Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Chair, Lung and Esophagus Task Force, American Joint Commission on Cancer Member, IASLC Staging Committee

HISTORY OF STAGING TNM Concept Describes extent of tumor: local (T = tumor) regional (N = nodes) distant (M = metastasis) Developed by Pierre Denoix 1943-52 Accepted by UICC in 1953 as basis for classification of anatomical extent of cancer Incorporated in 1 st edition of staging manual, 1968

HISTORY OF STAGING: UICC and AJCC From 1950-1980s, variations among staging systems 1987: Reconciliation of AJCC and UICC staging system Currently, AJCC and UICC agree jointly on revisions and publish simultaneously AJCC / UICC staging systems used worldwide and govern all US state and national tumor registries

Clifton F. Mountain, 1924-2007 Chief, Thoracic Surgery, M.D. Anderson Hospital and Tumor Institute, (Houston, TX) 1951-1986

LUNG CANCER STAGING In 1973, AJC proposed TNM staging system for lung cancer Based on 2155 cases in Mountain s database at MDACC Expanded database used by Mountain to propose revisions through 1997 (5 th editions) No data to recommend changes for 6 th editions of staging manuals

LUNG CANCER STAGING IASLC* Staging Committee & Database Following 1997 staging system revision, IASLC decided to sponsor development of international database 1999-2000, IASLC database organized by Peter Goldstraw (thoracic surgeon, Brompton, UK) and John Crowley (CRAB, Seattle, USA) IASLC Staging Committee is international and multidisciplinary * = International Association for the Study of Lung Cancer

LUNG CANCER STAGING IASLC Database 100,869 cases treated between 1990-2000 81,015 cases suitable for analysis (67,725 NSCLC, 13,290 SCLC, 513 carcinoid tumors) Evidence-based changes in T and M descriptors, maintenance of N descriptors Goldstraw et al. JTO 2007;2:706-714; multiple articles (Rami-Porta, Rusch, Postmus, Groome, Shepherd, Sculier, Travis) in JTO 2007-2009

NUMBERS OF CASES ANALYZED, by type of data source Registry 16,660 Series treated surgically 19,172 Clinical trial 24,239 Series treated by all 7866 modalities (incl surgery) Consortium 5912 Institutional registry 5492 Surgical registry 2154 TOTAL 81,495 Goldstraw et al. JTO 2006;1:281-286.

Goldstraw et al. JTO 2006;1:281-286.

Goldstraw et al. JTO 2006;1:281-286

Rami-Porta et al. J Thorac Oncol 2007;2:593-602.

Survival by cn and pn for Surgically Managed Patients Rusch VW et al. J Thorac Oncol, 2007;2:603-612.

Survival by N Status and Number of Involved N Zones Rusch VW et al. J Thorac Oncol, 2007;2:603-612.

Goldstraw et al. J Thorac Oncol 2007;2:706-714.

Overall survival, expressed as a median survival time (MST) and 5-year survival, by clinical stage using the sixth edition of TNM (A) and proposed IASLC recommendations (B). Goldstraw et al. J Thorac Oncol 2007;2:706-714

Overall survival, expressed as a median survival time (MST) and 5-year survival, by pathologic stage using sixth edition of TNM (A) and proposed IASLC recommendations (B) Goldstraw et al. J Thorac Oncol 2007; 2:706-714.

LUNG CANCER STAGING SYSTEM 7 th Edition: 2009 New staging system applies to: Non-small cell lung cancer Small cell lung cancer (replacing limited /extensive staging classification) Carcinoid tumors

Naruke vs. Mountain/Dresler Maps Comparison of Nomenclature Japanese Mountain / Dresler (ATS) Level 1 Levels 1 and 2 Levels 2, 3, 4R, 4L Levels 7 and 10 (subcarinal) Levels 4R and 4L Level 7 Rusch VW et al. J Thorac Oncol, 2007;2:603-612.

New IASLC Lymph Node Map Rusch & Asamura: JTO 2009; 4(5):568-577

Developing / Revising Staging Systems Evidence for proposed revisions requires: international & multidisciplinary participation statisticians capable of managing and analyzing huge datasets Prospective data collection key to future revisions for all thoracic malignancies IASLC staging committee will now also address mesothelioma, esophageal Ca and possibly thymoma

Naruke Lymph Node Map Japan Lung Cancer Society, Tokyo: Kanehara & Co, 2000.

Mountain Dresler Lymph Node Map Chest, 1997;111:1718-1723.